Literature DB >> 22133308

The combination of organoselenium compounds and guanosine prevents glutamate-induced oxidative stress in different regions of rat brains.

Cristiane L Dalla Corte1, Luíza L Bastos, Fernando Dobrachinski, João B T Rocha, Félix A A Soares.   

Abstract

This study was designed to investigate the protective effects of the combination of guanosine and 2 organoselenium compounds (ebselen and diphenyl diselenide) against glutamate-induced oxidative stress in different regions of rat brains. Glutamate caused an increase in reactive oxygen species (ROS) generation and a decrease in [(3)H]-glutamate uptake in striatal, cortical, and hippocampal slices. Guanosine, ebselen, and diphenyl diselenide prevented glutamate-induced ROS production in striatal, cortical and hippocampal slices. The combination of guanosine with organoselenium compounds was more effective against glutamate-induced ROS production than the individual compounds alone. Guanosine prevented [(3)H]-glutamate uptake inhibition in striatal, cortical, and hippocampal slices. Thus, protection against the harmful effects of glutamate is possibly due to the combination of the antioxidant properties of organoselenium compounds and the stimulatory effect of guanosine on glutamate uptake. In conclusion, the combination of antioxidants and glutamatergic system modulators could be considered a potential therapy against the prooxidant effects of glutamate.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133308     DOI: 10.1016/j.brainres.2011.10.049

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.

Authors:  Gajendra Kumar Azad; Raghuvir S Tomar
Journal:  Mol Biol Rep       Date:  2014-08       Impact factor: 2.316

2.  Rutin and Selenium Co-administration Reverse 3-Nitropropionic Acid-Induced Neurochemical and Molecular Impairments in a Mouse Model of Huntington's Disease.

Authors:  Mohamed S Abdelfattah; Sherif E A Badr; Sally A Lotfy; Gouda H Attia; Ahmed M Aref; Ahmed E Abdel Moneim; Rami B Kassab
Journal:  Neurotox Res       Date:  2019-07-22       Impact factor: 3.911

3.  2',3'-cGMP exists in vivo and comprises a 2',3'-cGMP-guanosine pathway.

Authors:  Edwin K Jackson; Zaichuan Mi; Keri Janesko-Feldman; Travis C Jackson; Patrick M Kochanek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-02-21       Impact factor: 3.619

4.  Guanosine ameliorates positive symptoms of schizophrenia via modulating 5-HT1A and 5-HT2A receptors.

Authors:  Yu Mao; Yao Xing; Jie Li; Dong Dong; Shoude Zhang; Zhenjiang Zhao; Jingli Xie; Rui Wang; Honglin Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 5.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

6.  Dysregulated metabolic pathways in age-related macular degeneration.

Authors:  Meng Zhang; Nisi Jiang; Yi Chu; Olga Postnikova; Rency Varghese; Anelia Horvath; Amrita K Cheema; Nady Golestaneh
Journal:  Sci Rep       Date:  2020-02-12       Impact factor: 4.379

Review 7.  Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders.

Authors:  Débora Lanznaster; Tharine Dal-Cim; Tetsadê C B Piermartiri; Carla I Tasca
Journal:  Aging Dis       Date:  2016-10-01       Impact factor: 6.745

Review 8.  Neuromodulatory Effects of Guanine-Based Purines in Health and Disease.

Authors:  Carla I Tasca; Débora Lanznaster; Karen A Oliveira; Victor Fernández-Dueñas; Francisco Ciruela
Journal:  Front Cell Neurosci       Date:  2018-10-23       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.